South Korea Medical Isotope Production Market Size, Share, Growth, and Industry Analysis, By Isotope Type (Diagnostic Isotopes, Therapeutic Isotopes), By Production Technology (Nuclear Reactor-Based Production, Fission-based, Neutron activation, Cyclotron-Based Production) and Forecast, 2026-2034

South Korea Medical Isotope Production Market Trends

Localization of Advanced Diagnostic and Therapeutic Radionuclides

South Korean isotope infrastructure is shifting beyond conventional PET radionuclides toward higher-value diagnostic and therapeutic products. KIRAMS reports operation of 3 cyclotrons and production or supply of isotopes including Cu-64, I-124, Zr-89 and At-211. Its accelerator portfolio includes Cyclone-30 and MC-50 systems, while KAERI's RFT-30 provides proton beams of 15–30 MeV at currents up to 300 μA.

Technology localization is also expanding isotope availability for oncology. KIRAMS established regular At-211 production, while its May 2025 Ac-225 authorization addressed an isotope previously dependent on imports. KAERI's RFT-30 facility produces F-18, N-13, C-11, Zr-89 and Ge-68 and identifies Sc-44, I-123, Co-57 and Cu-64 among planned production areas. These developments broaden domestic supply across PET imaging, targeted radionuclide therapy and pharmaceutical R&D.

South Korea Medical Isotope Production Market Drivers

Expanding Nuclear Medicine Infrastructure and Oncology Applications

Expansion of nuclear medicine capacity is supported by 39 operating cyclotrons, 3 KIRAMS cyclotrons and accelerator capabilities exceeding 30 MeV. KIRAMS has developed approximately 20 accelerator-produced radioisotopes and radiopharmaceuticals since installing Korea's first MC-50 accelerator in 1986. Current capabilities span PET and SPECT products such as F-18, I-123 and Tl-201, alongside emerging therapeutic radionuclides. The combination of 15–30 MeV proton facilities, up to 300 μA beam capability and growing isotope diversity strengthens domestic diagnostic and oncology supply.

South Korea Medical Isotope Production Market Restraints

Short Half-Lives and Concentrated High-Energy Production Capacity

Infrastructure concentration remains a constraint despite 39 operating cyclotrons. KIRAMS states that most Korean cyclotrons are low-energy hospital systems primarily used for PET, while its facility is the country's only medium-energy accelerator exceeding 30 MeV. Consequently, expansion into specialized radionuclides can require facilities operating across the 15–30 MeV range, dedicated targetry, separation and purification systems, and tightly coordinated logistics. These requirements raise technical barriers relative to routine short-lived PET isotope production.

South Korea Medical Isotope Production Market Opportunities

Domestic Production of Imported Therapeutic Isotopes

Therapeutic radionuclide localization creates a significant commercial opportunity. KIRAMS received the country's first Ac-225 production authorization on May 12, 2025 after the isotope had been entirely import-dependent, complementing regular At-211 production. Meanwhile, KAERI's 2026 supply program covers I-131 finished and active pharmaceutical products under a 1-year contract period from January 1 to December 31, 2026. Expanding from established I-131 supply into alpha-emitting radionuclides can strengthen domestic security of supply and targeted oncology development.

Challenges in South Korea Medical Isotope Production Market

Balancing Production Reliability, Regulation and Specialized Infrastructure

Medical radionuclides require simultaneous management of irradiation, purification, pharmaceutical manufacturing and regulated distribution. KAERI's 2026 I-131 supply arrangements require compliance with both Nuclear Safety Act and Pharmaceutical Affairs Act provisions, illustrating the dual regulatory burden. Specialized production additionally depends on proton energies reaching 30 MeV and beam currents up to 300 μA for some accelerator programs. Maintaining reliable output while developing multiple radionuclides across diagnostic, therapeutic and research workflows therefore remains technically and operationally demanding.

South Korea Medical Isotope Production Market Segmentation

Segmentation covers isotope type, production technology, application and end-user. Diagnostic isotopes account for approximately 55.6% of the supplied 2026 isotope-type value, while therapeutic isotopes contribute about 44.4%. Across the supplied production technologies, nuclear reactor-based production accounts for approximately 34.9% in 2026.

By Isotope Type

Diagnostic isotopes are the largest isotope category, increasing from USD 34.05 million in 2025 to USD 37.15 million in 2026 and USD 74.50 million by 2034, representing a 9.09% CAGR. Their 2026 contribution is approximately 55.6% of the supplied isotope-type total.

Therapeutic isotopes increase from USD 27.25 million in 2025 to USD 29.71 million in 2026 and USD 59.23 million in 2034, with a 9.01% CAGR. Diagnostic isotopes therefore also represent the faster-growing of the two supplied isotope-type categories at 9.09%.

By Production Technology

Nuclear reactor-based production is the largest supplied technology category, valued at USD 23.30 million in 2026 versus USD 21.46 million in 2025, and is forecast to reach USD 44.98 million by 2034 at an 8.57% CAGR. It accounts for approximately 34.9% of the supplied 2026 technology total.

Deuteron-based reactions are the fastest-growing supplied technology at a 9.28% CAGR, increasing from USD 3.37 million in 2026 to USD 6.85 million by 2034. Proton acceleration follows closely at 9.23%, while fission-based production advances at 9.20%.

By Application

Diagnostic applications represent a core utilization channel for PET and SPECT isotopes, while therapeutic applications are expanding through targeted radionuclides including At-211 and Ac-225. Research applications additionally support radiopharmaceutical development and isotope-labeled drug evaluation. Numerical application-level market values and CAGRs were not supplied and therefore are not imputed.

South Korean facilities already produce isotopes supporting all 3 application groups. KIRAMS reports diagnostic and therapeutic isotope programs, while KAERI's RFT-30 supports isotope development and basic scientific research at proton energies of 15–30 MeV.

By End-User

Hospitals and clinics and diagnostic imaging centers constitute established clinical users, complemented by academic institutes, pharmaceutical and biotechnology companies and CROs. The country's 39 cyclotrons demonstrate substantial hospital-linked production infrastructure. End-user market values and CAGRs were not included in the mandatory dataset and are therefore not estimated.

Research and biopharmaceutical users are gaining strategic importance as specialized isotopes become domestically available. KAERI has supplied domestically produced Zr-89 to hospitals, research institutes, universities and biotechnology companies since localizing its production technology in 2018, demonstrating demand across at least 4 institutional user categories.

South Korea Medical Isotope Production Market Outlook

South Korea contributes 100% of the geographic value covered by this country-level study, reaching USD 66.86 million in 2026 from USD 61.30 million in 2025 and advancing toward USD 133.73 million by 2034. No validated subnational revenue allocation was supplied, so Seoul, Gyeonggi, Daejeon, Jeongeup or other provincial percentage shares are not fabricated.

Seoul is an important accelerator-based production center through KIRAMS, which operates 3 cyclotrons and the country's only medium-energy accelerator exceeding 30 MeV. Jeongeup contributes through KAERI's RFT-30 facility, operating at 15–30 MeV and up to 300 μA for medical radioisotope development. Daejeon contributes through KAERI's reactor-centered isotope capabilities, including I-131 supply. Collectively, these locations support diagnostic imaging, therapeutic nuclear medicine and research-sector requirements.

Top players in South Korea Medical Isotope Production Market

1. Korea Atomic Energy Research Institute (KAERI)
2. Korea Institute of Radiological & Medical Sciences (KIRAMS)
3. Korea Cancer Center Hospital
4. Korea Radio-Isotope Center for Pharmaceuticals
5. Seoul National University Hospital
6. Samsung Medical Center
7. Asan Medical Center
8. Severance Hospital
9. SK Biopharmaceuticals
10. Samsung Biologics

Top Two Companies

• Korea Atomic Energy Research Institute (KAERI)

An audited company-level percentage cannot be derived from the supplied dataset. KAERI nevertheless occupies a central domestic position through reactor- and accelerator-related isotope infrastructure. Its RFT-30 cyclotron delivers 15–30 MeV proton beams at up to 300 μA and produces F-18, N-13, C-11, Zr-89 and Ge-68, with additional isotopes identified for development. KAERI also established 2026 supply arrangements for I-131 finished and active pharmaceutical products. Its capabilities therefore span production, isotope R&D and commercial supply rather than a single clinical channel.

• Korea Institute of Radiological & Medical Sciences (KIRAMS)

No reliable audited percentage is publicly disclosed in the reviewed sources, preventing defensible assignment of a numerical company share. KIRAMS operates 3 cyclotrons and has developed approximately 20 accelerator radioisotopes and radiopharmaceuticals since its first MC-50 installation. Its portfolio includes Cu-64, I-124, Zr-89 and regularly produced At-211. The May 2025 authorization for domestic Ac-225 production further strengthens its positioning in targeted alpha therapy and reduces reliance on imported therapeutic radionuclides.

Recent Developments in South Korea Medical Isotope Production Market

• 2025: KIRAMS obtained South Korea's first production authorization for Ac-225 on May 12, supporting localization of an isotope previously entirely import-dependent.
• 2025: KAERI exported domestically produced Zr-89 to China's C-Ray Therapeutics on October 23, extending exports after shipments to South Africa, Pakistan, and Thailand.
• 2025: KAERI announced contracts covering its 2026 supply of I-131 finished pharmaceuticals and I-131 active pharmaceutical ingredients.
• 2026: KAERI's annual I-131 supply contracts cover the January 1–December 31 period, maintaining domestic availability under nuclear-safety and pharmaceutical regulatory requirements.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period, with 2022–2024 treated as historical years. Mandatory numerical forecasts supplied for this report were retained without alteration except for calculated percentage contributions. Primary validation focused on KAERI and KIRAMS information concerning 39 cyclotrons, 3 KIRAMS cyclotrons, 15–30 MeV accelerator capacity, up to 300 μA beam current, isotope portfolios and 2025–2026 production developments. No unsupported subnational or company-level percentage estimates were introduced where verifiable data were unavailable.